Goserelin ( DrugBank: Goserelin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 1 | Spinal and bulbar muscular atrophy | 1 |
1. Spinal and bulbar muscular atrophy
Clinical trials : 18 / Drugs : 15 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 17
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00851461 (ClinicalTrials.gov) | April 2008 | 25/2/2009 | Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy | Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy in Thai Patients | Spinobulbar Muscular Atrophy;Kennedy's Disease | Drug: Goserelin;Procedure: Electrophysiologic study;Procedure: tissue biopsy | Ramathibodi Hospital | AstraZeneca | Completed | 20 Years | N/A | Male | 10 | Phase 4 | Thailand |